Previous 10 | Next 10 |
Global Blood Therapeutics (NASDAQ: GBT ): Q2 GAAP EPS of -$1.01 misses by $0.06 . More news on: Global Blood Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported recent business progress and financial results for the second quarter ended June 30, 2019. “We accomplished several significant milestones in the secon...
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 2019 Wedbush PacGrow Healthcare Conference in New York City on Tuesday, August 13, 2019, at 1:55 p.m. Eastern Time. The presentat...
Generosity is giving more than you can, and pride is taking less than you need. " - Khalil Gibran, Sand, and Foam Today, we revisit a mid-cap developmental company with a late-stage asset advancing in its pipeline that could carve out a significant niche if it approved as expected in 2020...
A cure for SCD (sickle cell disease) has long remained to be a far-fetched dream for the medical community. This is ironical, since for decades now, the medical fraternity is very well aware of the single gene mutation in the beta-chain of hemoglobin that leads to this hemoglobinopathy. The ar...
Introduction Published in June, The New England Journal of Medicine's article, titled " A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease ", provides detailed data and insights into Global Blood Therapeutic's ( GBT ) lead drug, voxelotor. Below, I will posit three rea...
Introduction Our 2019 Outlook highlighted our views on equity markets, The Fed, U.S. Dollar, CAPEX/Share buybacks, GDP growth, and S&P 500 earnings/Index targets. In our Mid-Year Outlook, we review our prior assumptions and provide our updated outlook for 2H19. Our updated global e...
Quick Take Fulcrum Therapeutics ( FULC ) has filed to raise gross proceeds of $76.5 million from a U.S. IPO, according to an S-1/A registration statement . The firm is developing treatments for genetically-defined diseases with high unmet medical need and an initial focus on rare diseases...
SOUTH SAN FRANCISCO, Calif., July 10, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), in partnership with sickle cell community-based organizations (CBOs), today announced the launch of Sickle Cell Speaks , a national campaign focused on breaking down stigma...
I have kept a close eye on Global Blood Therapeutics ( GBT ) over the past year and have come close to clicking the Buy button on multiple occasions. However, I always had a reason to hold off and retreat. The company’s recently publicized Voxelotor’s Phase III results in sickl...
News, Short Squeeze, Breakout and More Instantly...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
Global Blood Therapeutics Inc. Website:
Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...
The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...
NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...